Drugs & Targets Jaypirca receives FDA accelerated approval for R/R mantle cell lymphoma February 03, 2023Vol.49 No.05
Drugs & Targets Orserdu & companion diagnostic for ER+, HER2-, ESR1-mutated advanced breast cancer receive FDA approval February 03, 2023Vol.49 No.05
Drugs & Targets RefleXion receives FDA clearance for SCINTIX biology-guided radiotherapy February 03, 2023Vol.49 No.05
Drugs & Targets FLAG Therapeutics’s FLAG-003 receives Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma February 03, 2023Vol.49 No.05
Epigeneticists may be looking for epigenome-disease associations in the wrong place January 27, 2023Vol.49 No.04By Jacquelyn Cobb and Matthew Bin Han Ong
Conversation with The Cancer Letter Baylor’s Waterland & Coarfa: We see CoRSIVs as the new standard in epigenetic epidemiology January 27, 2023Vol.49 No.04By Jacquelyn Cobb and Matthew Bin Han Ong
Guest Editorial NIH, NCI face devastating cuts in debt ceiling fight; We must rally for biomedical research January 27, 2023Vol.49 No.04By Lisa M. Coussens
In Brief Richard D. Carvajal named deputy physician-in-chief and director of medical oncology at Northwell Health Cancer Institute January 27, 2023Vol.49 No.04
